- Home
- EWTX vs MNKD Comparison
EWTX vs MNKD Comparison
Compare EWTX & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWTX
- MNKD
- Stock Information
- Founded
- EWTX 2017
- MNKD 1991
- Country
- EWTX United States
- MNKD United States
- Employees
- EWTX N/A
- MNKD N/A
- Industry
- EWTX Biotechnology: Pharmaceutical Preparations
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- EWTX Health Care
- MNKD Health Care
- Exchange
- EWTX Nasdaq
- MNKD Nasdaq
- Market Cap
- EWTX 1.5B
- MNKD 1.2B
- IPO Year
- EWTX 2021
- MNKD 2004
- Fundamental
- Price
- EWTX $13.93
- MNKD $3.69
- Analyst Decision
- EWTX Buy
- MNKD Buy
- Analyst Count
- EWTX 8
- MNKD 6
- Target Price
- EWTX $41.13
- MNKD $9.17
- AVG Volume (30 Days)
- EWTX 633.0K
- MNKD 3.1M
- Earning Date
- EWTX 08-07-2025
- MNKD 08-06-2025
- Dividend Yield
- EWTX N/A
- MNKD N/A
- EPS Growth
- EWTX N/A
- MNKD 149.32
- EPS
- EWTX N/A
- MNKD 0.11
- Revenue
- EWTX N/A
- MNKD $301,736,000.00
- Revenue This Year
- EWTX N/A
- MNKD $13.62
- Revenue Next Year
- EWTX N/A
- MNKD $15.18
- P/E Ratio
- EWTX N/A
- MNKD $34.29
- Revenue Growth
- EWTX N/A
- MNKD 21.48
- 52 Week Low
- EWTX $10.60
- MNKD $3.38
- 52 Week High
- EWTX $38.12
- MNKD $7.63
- Technical
- Relative Strength Index (RSI)
- EWTX 52.63
- MNKD 45.90
- Support Level
- EWTX $12.30
- MNKD $3.38
- Resistance Level
- EWTX $14.11
- MNKD $3.81
- Average True Range (ATR)
- EWTX 0.73
- MNKD 0.18
- MACD
- EWTX 0.00
- MNKD -0.01
- Stochastic Oscillator
- EWTX 53.80
- MNKD 35.14
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.